Regardless of the sequential decrease in Current Liabilities, during the first quarter 2025, Quick Ratio deteriorated to 2.5 below Acelyrin Inc 's average Quick Ratio.

Within Major Pharmaceutical Preparations industry 210 other companies have achieved higher Quick Ratio than Acelyrin Inc in first quarter 2025. While Quick Ratio total ranking in the first quarter 2025 has deteriorated compared to the prior quarter from 611 to 739.

Explain Quick Ratio?
How much Cash & cash equivalents SLRN�s has?
What are SLRN�s Current Liabilities?

Select the Comparisons :

None ▼

Select the Ratio:

Quick Ratio ▼

None ▼

Quick Ratio ▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

SLRN Quick Ratio	(Mar 31 2025) Q1	(Dec 31 2024) Q4	(Sep 30 2024) Q3	(Jun 30 2024) Q2	(Mar 31 2024) Q1
Y / Y Current Liabilities Change	-55.43 %	-36.6 %	346.32 %	803.39 %	385.45 %
Y / Y Cash & cash equivalent Change	-77.97 %	-66.12 %	-43.33 %	-76.95 %	-8.54 %
Quick Ratio MRQ	2.5	2.78	2.59	1.55	5.06
SLRN's Total Ranking	# 739	# 611	# 874	# 1224	# 382
Seq. Current Liabilities Change	-12.32 %	-68.16 %	1.24 %	57.7 %	24.72 %
Seq. Cash & cash equivalent Change	-21.14 %	-65.84 %	68.73 %	-51.53 %	21.28 %

Quick Ratio first quarter 2025 Company Ranking
Within:	No.
Major Pharmaceutical Preparations Industry	# 211
Healthcare Sector	# 361
Overall Market	# 739

Quick Ratio Statistics
High	Average	Low
60.94	14.21	1.55
(Jun 30 2023)		(Jun 30 2024)

Financial Statements
Acelyrin Inc 's Current Liabilities	$ 23 Millions	Visit SLRN's Balance sheet
Acelyrin Inc 's Cash & cash equivalent	$ 58 Millions	Visit SLRN's Balance sheet
Source of SLRN's Sales		Visit SLRN's Sales by Geography

Cumulative Acelyrin Inc 's Quick Ratio

SLRN's Quick Ratio for the trailling 12 Months

SLRN Quick Ratio	(Mar 31 2025) 12 Months	(Dec 31 2024) 12 Months	(Sep 30 2024) 12 Months	(Jun 30 2024) 12 Months	(Mar 31 2024) 12 Months
Y / Y Current Liabilities TTM Growth	76.84 %	204.01 %	339.19 %	382.04 %	288.64 %
Y / Y Cash & cash equivalent TTM Growth	-66.44 %	-52.75 %	-44.65 %	-10.79 %	155.31 %
Quick Ratio TTM	2.21	2.79	3.18	5.08	11.64
Total Ranking TTM	# 4030	# 2360	# 3235	# 3179	# 241
Seq. Current Liabilities TTM Growth	-11.84 %	-5.9 %	33.15 %	60.09 %	51.56 %
Seq. Cash & cash equivalent TTM Growth	-30.2 %	-17.43 %	-16.67 %	-30.13 %	-1.71 %

Quick ratio ranking by company, industry and sector >> Back to SLRN Financial Strength Comparisons >> Go to Compare SLRN Quick Ratio to its Competitors

On the trailing twelve months basis In spite of the year on year decrease in SLRN's Current Liabilities to $23.30 millions, cumulative Quick Ratio to 2.21 below the SLRN average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 509 other companies have achieved higher Quick Ratio than Acelyrin Inc . While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the fourth quarter 2024 from 2360 to 4030.

Explain Quick Ratio?
How much Cash & cash equivalents SLRN�s has?
What are SLRN�s Current Liabilities?

TTM Quick Ratio Company Ranking
Within:	No.
Within the Major Pharmaceutical Preparations Industry	# 510
Healthcare Sector	# 1016
Within the Market	# 4030

trailing twelve months Quick Ratio Statistics
High	Average	Low
6.62	3.97	2.21
(Dec 31 2023)		(Mar 31 2025)

Companies with similar Quick Ratio in the quarter ending Mar 31 2025, within Major Pharmaceutical Preparations Industry	Quick Ratio	Mar 31 2025 MRQ Cash & cash equivalent	Mar 31 2025 MRQ Current Liabilities
Galera Therapeutics Inc	6.86	$ 6.686 Millions	$ 0.975 Millions
Lisata Therapeutics Inc	6.79	$ 25.833 Millions	$ 3.807 Millions
Kezar Life Sciences Inc	6.74	$ 114.361 Millions	$ 16.963 Millions
Cytokinetics Incorporated	6.69	$ 938.218 Millions	$ 140.152 Millions
Uniqure N v	6.66	$ 217.229 Millions	$ 32.612 Millions
Sensei Biotherapeutics Inc	6.57	$ 34.331 Millions	$ 5.229 Millions
Lipella Pharmaceuticals Inc	6.50	$ 4.225 Millions	$ 0.650 Millions
Kalvista Pharmaceuticals Inc	6.49	$ 220.617 Millions	$ 33.983 Millions
Metsera Inc	6.48	$ 588.335 Millions	$ 90.741 Millions
Zentalis Pharmaceuticals Inc	6.48	$ 320.302 Millions	$ 49.430 Millions
Galmed Pharmaceuticals Ltd	6.38	$ 18.156 Millions	$ 2.845 Millions
Vistagen Therapeutics Inc	6.38	$ 80.482 Millions	$ 12.612 Millions
Zenas Biopharma Inc	6.36	$ 312.379 Millions	$ 49.132 Millions
Silence Therapeutics Plc	6.33	$ 157.283 Millions	$ 24.843 Millions
Cybin Inc	6.30	$ 103.427 Millions	$ 16.406 Millions
Alzamend Neuro Inc	6.22	$ 3.949 Millions	$ 0.635 Millions
Amarin Corp Plcuk	6.18	$ 282.087 Millions	$ 45.661 Millions
Tango Therapeutics Inc	6.03	$ 216.724 Millions	$ 35.917 Millions
Oramed Pharmaceuticals Inc	5.72	$ 30.396 Millions	$ 5.311 Millions
Puretech Health Plc	5.59	$ 258.842 Millions	$ 46.309 Millions
Marker Therapeutics inc	5.47	$ 13.693 Millions	$ 2.501 Millions
Syndax Pharmaceuticals Inc	5.46	$ 516.313 Millions	$ 94.551 Millions
Lava Therapeutics Nv	5.46	$ 106.274 Millions	$ 19.468 Millions
Nucana Plc	5.43	$ 34.978 Millions	$ 6.445 Millions
Ovid Therapeutics Inc	5.41	$ 42.996 Millions	$ 7.947 Millions
Igm Biosciences Inc	5.39	$ 152.112 Millions	$ 28.198 Millions
Gossamer Bio Inc	5.35	$ 257.934 Millions	$ 48.223 Millions
Immutep Limited	5.28	$ 44.307 Millions	$ 8.386 Millions
Longeveron Inc	5.26	$ 14.327 Millions	$ 2.724 Millions
Alx Oncology Holdings Inc	5.22	$ 97.831 Millions	$ 18.742 Millions

Date modified: 2026-09-26T07:42:31+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.